Provided by Tiger Trade Technology Pte. Ltd.

Biogen

216.78
+2.431.13%
Post-market: 216.780.00000.00%19:30 EDT
Volume:722.35K
Turnover:156.95M
Market Cap:32.00B
PE:38.50
High:219.12
Open:217.76
Low:215.00
Close:214.35
52wk High:222.15
52wk Low:131.52
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.01
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.70
PE(LYR):24.66

Loading ...

Biogen Q2 Non-GAAP Earnings Fall, Revenue Rises; Lowers 2026 EPS Guidance

MT Newswires Live
·
Jul 29

Biogen - Amount of Ieepa Tariff Refunds, if Any, That We Ultimately Recover May Differ from the Full Amount We Previously Paid

THOMSON REUTERS
·
Jul 29

Biogen - Do not Expect Tariffs Currently Applicable to Our Business to Result in Material Adverse Effect on Operations in 2026 - Filing

THOMSON REUTERS
·
Jul 29

Biogen - Middle East Conflict Did not Have Any Material Effects on Our Results of Operations for Three and Six Months Ended June 30, 2026

THOMSON REUTERS
·
Jul 29

Biogen - for Apellis Integration, for Three and Six Months Ended June 30, 2026, We Recognized $153.2 Million of Net Pre-Tax Restructuring Charges

THOMSON REUTERS
·
Jul 29

Biogen - We Have not Recorded a Receivable for Any Refund of Ieepa Tariffs

THOMSON REUTERS
·
Jul 29

GUIDANCE: (BIIB) Biogen Expects 2026 Adjusted EPS Range $12.00 to $13.00, vs. FactSet Est of $12.63

MT Newswires Live
·
Jul 29

Biogen Q2 Revenue Beats Expectations on Strong Product Demand

Reuters
·
Jul 29

Earnings Flash (BIIB) Biogen Posts Q2 Total Revenue $2.74B, vs. FactSet Est of $2.46B

MT Newswires Live
·
Jul 29

Biogen Q2 Adj. EPS $3.60 Beats $2.96 Estimate, Sales $2.736B Beat $2.458B Estimate

Benzinga Earnings
·
Jul 29

Biogen lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25

TIPRANKS
·
Jul 29

Biogen Q2 Revenue USD 2,700 Million VS. Ibes Estimate USD 2,458 Million

THOMSON REUTERS
·
Jul 29

Biogen Cuts FY Adjusted View as 2Q Profit Declines

Dow Jones
·
Jul 29

Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

Dow Jones
·
Jul 29

Biogen Q2 FY26 GAAP Diluted EPS Drops 85% to $0.66; Revenue Rises 3% to $2.74 Billion

Reuters
·
Jul 29

Biogen Q2 Leqembi Global in-Market Sales $184 Mln, up 15% YoY

THOMSON REUTERS
·
Jul 29

Biogen: Conversion to High-Dose Spinraza Regimen Ahead of Co's Expectations in All Launched Geographies

THOMSON REUTERS
·
Jul 29

Biogen Outlook FY REV Expected to Increase by Mid-Single Digit Percentage

THOMSON REUTERS
·
Jul 29

Biogen Q2 REV $2.74 Bln vs Ibes Estimate $2.46 Bln

THOMSON REUTERS
·
Jul 29

Biogen Outlook Expected Dilution from Apellis Deal on FY Adj EPS $-0.85

THOMSON REUTERS
·
Jul 29